Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dr Reddys Laboratories (RDY) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to $371.3 million.

  • Dr Reddys Laboratories' Operating Expenses rose 335.94% to $371.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $713.3 million, marking a year-over-year decrease of 3137.33%. This contributed to the annual value of $1.4 billion for FY2025, which is 2069.57% up from last year.
  • According to the latest figures from Q4 2025, Dr Reddys Laboratories' Operating Expenses is $371.3 million, which was up 335.94% from $342.0 million recorded in Q1 2025.
  • Dr Reddys Laboratories' 5-year Operating Expenses high stood at $371.3 million for Q4 2025, and its period low was $178.9 million during Q2 2022.
  • Over the past 5 years, Dr Reddys Laboratories' median Operating Expenses value was $272.2 million (recorded in 2023), while the average stood at $287.3 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first plummeted by 3091.16% in 2022, then surged by 4912.6% in 2023.
  • Quarter analysis of 5 years shows Dr Reddys Laboratories' Operating Expenses stood at $253.0 million in 2021, then grew by 12.45% to $284.5 million in 2022, then increased by 5.27% to $299.5 million in 2023, then grew by 19.96% to $359.2 million in 2024, then increased by 3.36% to $371.3 million in 2025.
  • Its last three reported values are $371.3 million in Q4 2025, $342.0 million for Q1 2025, and $359.2 million during Q4 2024.